A critical first-line element of mammalian innate immunity is the function of phagocytic cells, in particular neutrophils and macrophages. The effectiveness of these specialized leukocytes in host defense reflects their capacity for directed migration, microbial uptake, and intra-and extracellular microbial killing; the latter is achieved through the concerted action of reactive oxygen species, enzymatic proteolysis, and cationic antimicrobial peptides. Stimulated phagocytes also amplify inflammatory and immune responses through the release of cytokines, nitric oxide, and vasoactive peptides. Their general importance is further exemplified by the increased susceptibility to invasive bacterial infection in patients whose phagocyte numbers are markedly reduced. However, it is also apparent that several leading bacterial pathogens such as Staphylococcus aureus , Streptococcus pyogenes , and others are capable of causing severe invasive infections even in previously healthy individuals. Such intrinsic disease-producing capacity defines a superior ability of these pathogens to resist host phagocytic clearance through the coordinated expression of virulence determinants that interfere with phagocyte trafficking or opsonophagocytosis, or instead to neutralize the molecular effectors of bacterial killing. This special thematic issue of the Journal of Innate Immunity focuses on the elucidation of new bacterial virulence factors that target phagocyte defense pathways, pointing out the significant consequences they hold for the pathogen-host encounter. After a phagocyte engulfs a bacteria, a critical ensuing step in the killing process is the fusion of the phagosome with cellular structures such as lysosomes (macrophages) or specific or azurophil granules (neutrophils) which can deliver cargos of hydrolytic enzymes, proteases, and cationic peptides with potent bactericidal properties. Here Cederlund et al. [6] provide a sophisticated analysis of the activities of several such bactericidal effectors, including lysosomes, ␣ -defensins, azurocidin, cathelicidin LL-37, calprotectin, and lactotransferrin, showing that specificity in the killing of different bacterial pathogens is provided by distinct repertoires of these bioactive peptides. One way for a bacterial pathogen to resist phagocyte killing is thus to prevent phagosome fusion with lysosomes and granules. Huynh et al. [7] demonstrate that the opportunistic pathogen Burkholderia cepacia is able to impair the activation of Rab7, a small GTPase that plays a key role in lysosome biogenesis and fusion with late endocytic structures [8] . For the invasive M1 serotype strain of the pathogen S. pyogenes , Hertzén et al. [9] show that the surface-expressed M1 protein prevents the fusion of the phagosome with the lysosome and provides the bacteria with an intracellular safe haven, creating a reservoir of surviving bacteria that can subsequently egress the macrophage to reinfect new cells.
S. aureus , a leading cause of serious bacterial infections and increasing antibiotic resistance, is capable of promoting the rapid elimination of human neutrophils.
One key mechanism appears to be the action of staphopain B, a cysteine protease that selectively cleaves CD11b on phagocytic cells; this is a 'cell death signal' which promotes rapid clearance of the affected neutrophils by macrophages thus reducing the number of phagocytes at the site of infection [10, 11] . In this issue, 2 articles explore rapid neutrophil lysis induced by the epidemic USA300 clone of methicillin-resistant S. aureus (MRSA). Pang et al. [12] report that a global regulator of virulence factors, the agr system, is activated upon phagocytosis of USA300 MRSA leading to the upregulated expression of the poreforming ␣ -hemolysin within the phagosome and contributing to neutrophil destruction in as little as 2 h. Kobayashi et al. [13] use live-cell imaging, electron microcopy, and whole-genome expression analysis to reveal that both low-and high-hemolysin-producing strains can induce such rapid neutrophil death. In these studies, neutrophil phagosome membranes appear to remain intact right up to the point of cell lysis, suggesting that USA300 MRSA triggers a novel form of programmed cell necrosis, a signature phenotype for its hypervirulence.
An important emerging concept in the field of neutrophil biology is that phagocytosis is not the sine qua non of bacterial killing. Rather, neutrophils can themselves undergo a specialized form of cell death that enhances innate immunity -the formation of neutrophil extracellular traps or NETs [14] . These structures comprise a backbone lattice of nuclear or mitochondrial DNA decorated with antimicrobial peptides, histones, and granule proteases that can ensnare and kill bacterial pathogens [15, 16] . Berends et al. [17] report that S. aureus can thwart this extracellular killing mechanism by the elaborat ion of secreted nucleases that degrade the DNA backbone to dissolve the NETs. S . pyogenes strongly stimulates NET production by the proinflammatory action of its M1 protein in complex with fibrinogen [18] , yet it can resist entrapment and killing by nuclease production [19] or binding and inactivation of the embedded cathelicidin antimicrobial peptides mediated by the M1 protein [20] . In the present issue, Pence et al. [21] use targeted mutagenesis and heterologous gene expression to show that the streptococcal inhibitor of complement (SIC), expressed by M1 strains of S. pyogenes , also inhibits cathelicidin killing to promote phagocyte resistance and systemic virulence. SIC, nuclease, capsule, and other neutrophil resistance factors of M1 S. pyogenes are upregulated in vivo as the result of selective pressure for mutations in the covRS 2-component regulator. Maamary et al. [22] show that a reduced propensity for covRS mutation predicts the increased neutrophil susceptibility and lower invasive disease potential of non-M1 S. pyogenes strains.
More than a century ago, Bail [4] foresaw that the neutralization of bacterial 'aggressins' could represent an important aspect of infectious disease therapy. While some of the virulence mechanisms discussed herein (e.g. S. aureus ␣ -hemolysin or staphopain B) do lead to the aggressive destruction of the phagocytic cell, others (e.g. S. pyogenes M1 protein or SIC and S. aureus nuclease) simply allow the pathogen to withstand the antimicrobial killing mechanisms deployed by the phagocyte and continue its replication in vivo (Author's note: perhaps virulence factors in the latter category might lightheartedly be referred to as 'passive aggressins').
The life-or-death battles between bacterial pathogens and host phagocytes will remain a critical determinative factor dictating infectious disease resolution or progression. Identification of the molecular effectors of bacterial phagocyte resistance can thus provide the novel opportunities for therapy suggested by Bail [4] . In this context, the therapeutic agent is not a classical antibiotic designed to kill the microbe directly, but rather a drug that 'disarms' the pathogen facilitating clearance by the host's normal phagocytic cell defenses. Proof-of-principle examples include a drug that blocks synthesis of the golden staphyloxanthin pigment of S. aureus , thus increasing the sensitivity to phagocyte oxidative burst [23] , a molecule that inhibits protein kinase G of Mycobacterium tuberculosis to promote normal phagolysosome fusion [24] , and an inhibitor of S. pyogenes DNase that preserves NETs and extracellular bacterial killing [19] . Continued elucidation of pathways and virulence factors conferring phagocyte resistance, as illustrated by the studies of this issue, can serve as a template for a new generation of targeted antimicrobials with increased specificity and reduced selective pressure for the spread of antimicrobial resistance.
